20171113-三星证券-Samsung_Healthcare_Weekly_17页_1mb

Sector Update Summary

Core Content Overview

This document provides a comprehensive update on the performance of the Korean healthcare sector, global biotechnology and life sciences firms, and global healthcare equipment and services. It includes market capitalization, forward P/E and P/B ratios, and year-to-date (YTD) returns for the top companies in these sectors, as well as performance metrics for various indices and individual firms. The report is prepared by Samsung Healthcare analysts, including Brian Lee (Team Head), SunYoung Yoon, and Kevin Kim, with Wonyong Park as the Research Associate.

Main Points

Korean Stock Market (Top 20)

• Samsung Electronics leads with a market cap of 364.1 KRWt and a YTD return of 56.5%.
• SK Hynix is the second with a market cap of 59.7 KRWt and a YTD return of 83.5%.
• Hyundai Motor and LG Chem are among the top performers with YTD returns of 5.8% and 55.8%, respectively.
• Samsung Biologics is ranked 11th with a market cap of 24.8 KRWt and a YTD return of 148.7%, indicating strong performance.
• AmorePacific is at the bottom of the list with a YTD return of -0.3%.

Global Biotechnology, Life Sciences Tools, and Services (Top 20)

• AbbVie is the leader with a market cap of 152.3 USDb and a YTD return of 52.4%.
• Amgen is second with a market cap of 125.1 USDb and a YTD return of 17.9%.
• Gilead Sciences and Thermo Fisher Scientific are notable with YTD returns of 3.0% and 31.9%, respectively.
• Celltrion+Celltrion Healthcare and Samsung Biologics are highlighted in the list with YTD returns of 54.5% and 148.7%, respectively.
• Vertex Pharmaceuticals has the highest forward P/E of 79.0 and a YTD return of 101.9%, suggesting high valuation and growth potential.

Global Healthcare Indices

Key Performance Highlights

• Samsung Biologics and Celltrion show strong YTD returns in both Korean and global rankings.
• Amgen and Thermo Fisher Scientific are top global performers with significant market caps and returns.
• Vertex Pharmaceuticals has the highest forward P/E ratio, indicating high valuation.
• KRX Health Care and Kosdaq Pharmaceuticals are among the top Korean indices with notable performance.
• MSCI Japan Healthcare Equipment and Services and MSCI China Healthcare show positive returns.

Key Information

• The data is sourced from QuantiWise, Bloomberg, and Samsung Securities.
• Forward P/E and Forward P/B are used as valuation metrics.
• YTD returns indicate the performance of the companies and indices over the year.
• The report includes detailed performance metrics for Korean healthcare firms and global biotech firms, with a focus on Pharmaceutical holdings, Pharmaceuticals, Biosimilars, Diagnostics, Genome analysis, New drug development, Functional foods, and Medical devices.
• SLB balance and weekly share performance are visualized in charts and images, which are referenced in the report.

Summary of Major Korean Healthcare Firms

• Samsung Biologics and Celltrion have high market caps and YTD returns, showing strong performance.
• Hanmi Science and Green Cross Holdings are significant pharmaceutical holdings with notable YTD returns.
• Daewoong and Donga Socio Holdings are among the top pharmaceutical companies, with varying performance metrics.
• Medical devices firms like Osstem Implant, Dentium, and InBody are highlighted for their performance and market positions.

Conclusion

The report highlights the strong performance of several Korean and global healthcare companies and indices, with a focus on biotechnology, pharmaceuticals, and medical equipment and services. Companies such as Samsung Biologics and Celltrion are leading in terms of market cap and YTD returns, while AbbVie and Amgen are top global biotech firms. The data suggests a dynamic and growing healthcare sector, with significant investment potential in both Korean and international markets.